Get the Stockscreener App
0.36
0.00%
0.00
After Hours:
.36
Turnstone Biologics Corp stock is traded at $0.36, with a volume of 33,669.
It is up +0.00% in the last 24 hours and down -0.83% over the past month.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
See More
Previous Close:
$0.36
Open:
$0.3674
24h Volume:
33,669
Relative Volume:
0.09
Market Cap:
$8.33M
Revenue:
$81.89M
Net Income/Loss:
$-55.20M
P/E Ratio:
-0.1335
EPS:
-2.6959
Net Cash Flow:
$-67.40M
1W Performance:
-0.25%
1M Performance:
-0.83%
6M Performance:
-21.74%
1Y Performance:
-85.66%
1-Day Range:
$0.3551
$0.3674
1-Week Range:
$0.3526
$0.3674
52-Week Range:
$0.29
$2.59
Turnstone Biologics Corp Stock (TSBX) Company Profile
Name
Turnstone Biologics Corp
Sector
Industry
Phone
347-897-5988
Address
9310 ATHENA CIRCLE, SUITE 300, LA JOLLA
Compare TSBX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSBX
Turnstone Biologics Corp
|
0.36 | 8.33M | 81.89M | -55.20M | -67.40M | -2.6959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Turnstone Biologics Corp Stock (TSBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-15-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-14-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-16-23 | Initiated | SVB Securities | Market Perform |
| Aug-15-23 | Initiated | BofA Securities | Buy |
| Aug-15-23 | Initiated | Piper Sandler | Overweight |
View All
Turnstone Biologics Corp Stock (TSBX) Latest News
What does TSBX's flat EPS in 2024 suggest for future quarters? - AInvest
What analysts say about Turnstone Biologics Corp. stockRapidly expanding wealth - PrintWeekIndia
What analysts say about Turnstone Biologics Corp. stock outlookRapid growth trajectories - jammulinksnews.com
Is Turnstone Biologics Corp. a good long term investmentFree Investment Risk Control - PrintWeekIndia
What drives Turnstone Biologics Corp. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
Why Turnstone Biologics Corp. stock attracts strong analyst attentionTop Gaining Low Risk Assets - Newser
Turnstone Biologics Corp. Stock Analysis and ForecastRapid growth opportunities - jammulinksnews.com
What makes Turnstone Biologics Corp. stock price move sharplyVerified Chart Patterns - Newser
How Turnstone Biologics Corp. stock performs during market volatilityLow Risk Trade Timing Signals - Newser
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - The Malaysian Reserve
How did TSBX's revenue and expenses trend in Q4 2024? - AInvest
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX) - TradingView
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
XOMA stock rises after acquisition of Turnstone Biologics By Investing.com - Investing.com India
Turnstone Biologics Corp Stock (TSBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):